PortfoliosLab logoPortfoliosLab logo
ISIN
US68277Q1058
IPO Date
Oct 7, 2024

Highlights

Market Cap
$57.71M
Enterprise Value
-$133.58M
EPS (TTM)
-$3.22
Gross Profit (TTM)
-$202.00K
EBITDA (TTM)
-$60.95M
Year Range
$1.91 - $5.38
Target Price
$35.00
ROA (TTM)
-21.94%
ROE (TTM)
-23.65%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


OnKure Therapeutics, Inc

Often compared with OKUR:
OKUR vs. TARA

Performance

OKUR Performance Chart

OnKure Therapeutics, Inc (OKUR) is up 45.5% since the beginning of the year. At $4 per share, OKUR is trading 21.6% below its 52-week high of $5.


Loading charts...

S&P 500 Index

Returns By Period

OnKure Therapeutics, Inc (OKUR) has returned 45.52% so far this year and 59.25% over the past 12 months.


OnKure Therapeutics, Inc

1D
0.48%
1M
-10.78%
YTD
45.52%
6M
61.07%
1Y
59.25%
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.25%
YTD
11.16%
6M
11.43%
1Y
28.20%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

OKUR Monthly Returns History

Based on dividend-adjusted daily data since Oct 7, 2024, OKUR's average daily return is -0.25%, while the average monthly return is -4.30%.

Historically, 38% of months were positive and 62% were negative. The best month was Mar 2026 with a return of +52.8%, while the worst month was Dec 2024 at -44.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, OKUR closed higher 40% of trading days. The best single day was Aug 13, 2025 with a return of +20.0%, while the worst single day was Apr 4, 2025 at -19.5%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-8.97%2.65%52.77%27.29%-20.30%0.48%45.52%
2025-28.49%-17.56%-15.19%-42.09%1.61%-5.53%-7.53%24.43%0.00%23.27%-11.21%-3.65%-66.28%
2024-6.17%-11.89%-44.23%-53.89%

Benchmark Metrics

OnKure Therapeutics, Inc has an annualized alpha of -56.43%, beta of 1.03, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 08, 2024.

  • This stock participated in 336.24% of S&P 500 Index downside but only -61.75% of its upside - more exposed to losses than it benefited from rallies.
  • R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-56.43%
Beta
1.03
0.05
Upside Capture
-61.75%
Downside Capture
336.24%

Return for Risk

Risk / Return Rank

OKUR ranks 66 for risk / return — better than 66% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


OKUR Risk / Return Rank: 6666
Overall Rank
OKUR Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
OKUR Sortino Ratio Rank: 6868
Sortino Ratio Rank
OKUR Omega Ratio Rank: 6363
Omega Ratio Rank
OKUR Calmar Ratio Rank: 6767
Calmar Ratio Rank
OKUR Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for OnKure Therapeutics, Inc (OKUR) and compare them to S&P 500 Index.


OKURBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.80

2.39

-1.59

Sortino ratio

Return per unit of downside risk

1.64

3.25

-1.61

Omega ratio

Gain probability vs. loss probability

1.18

1.43

-0.25

Calmar ratio

Return relative to maximum drawdown

1.43

3.11

-1.68

Martin ratio

Return relative to average drawdown

3.29

14.38

-11.09

Dividends

Dividend History


OnKure Therapeutics, Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the OnKure Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the OnKure Therapeutics, Inc was 90.47%, occurring on May 14, 2025. The portfolio has not yet recovered.

The current OnKure Therapeutics, Inc drawdown is 78.03%.


Related event

Drawdown

Fall

Recovery

Underwater

2025 selloff2025
-90.47%May 2025
7mo 7d
1y 7moOct 2024 - now

Drawdown Indicators


OKURBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-90.47%

-56.78%

-33.69%

Max Drawdown (1Y)

Largest decline over 1 year

-41.56%

-9.10%

-32.46%

Max Drawdown (3Y)

Largest decline over 3 years

-18.90%

Max Drawdown (5Y)

Largest decline over 5 years

-25.43%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-78.03%

0.00%

-78.03%

Average Drawdown

Average peak-to-trough decline

-73.49%

-10.72%

-62.77%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.08%

1.97%

+16.11%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of OnKure Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how OnKure Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for OKUR in comparison with other companies in the Biotechnology industry. Currently, OKUR has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with OKUR

Add OnKure Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with OKUR